Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy
Chengdu, China 14 October 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 million (~USD 10.6 million) from new Chinese investors. The seed extension financing was led by Three Rivers Capital, who joins existing private Chinese investors. The total raised in the seed round is now over USD31 million (around CNY 200 million).
